Background: Maintenance treatment with vinorelbine and oral cyclophosphamide (oral-CPM) improves outcome of nonmetastatic high-risk (HR) and very-high risk (VHR) rhabdomyosarcoma (RMS) patients. However, gonadal toxicity of maintenance was not yet investigated.
Methods: The authors focused their analysis on male gonadal toxicity in HR/VHR groups of RMS2005 trial, in France.